TWC
CRNX

TD Waterhouse Canada’s Crinetics Pharmaceuticals CRNX Stock Holding History

TD Waterhouse Canada’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.81K Hold
150
– – ﹤0.01% 1946
2026
Q1 		$5.46K Buy
+150
New +$6.7K ﹤0.01% 1884

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TD Waterhouse Canada's CRNX Position: Q2 2026 in Review

TD Waterhouse Canada held its Crinetics Pharmaceuticals (CRNX) position steady in Q2 2026 at 150 shares worth $5.81K. The position accounts for ﹤0.01% of the portfolio, ranked #1946.

TD Waterhouse Canada first reported a position in CRNX in Q1 2026 and has held it in 2 quarters since. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • TD Waterhouse Canada held 150 shares of Crinetics Pharmaceuticals worth $5.81K as of Q2 2026.
  • TD Waterhouse Canada left its Crinetics Pharmaceuticals share count unchanged in Q2 2026.
  • Crinetics Pharmaceuticals made up ﹤0.01% of TD Waterhouse Canada's portfolio in Q2 2026, its #1946 holding.
  • TD Waterhouse Canada first reported a position in Crinetics Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on TD Waterhouse Canada's 13F filing for Q2 2026, filed 27 Jul 2026.